Skip to main content
Livermore
Livermore
ZHEN

Inozyme Pharma, Inc.

INZYDelisted Jul 1, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001693011

Inozyme Pharma, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 3, 2025; 87 institutions reported holding it in 13F filings for Q2 2025, worth $202.3M in total; no superinvestor held it.

13F holders, Q1 2022

Institutional positions in Inozyme Pharma, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
50
−1 vs. Q4 2021
Shares held
17.4M
+78.2K (+0.5%) vs. Q4 2021
Total value
$71.2M
−$47.0M (−39.8%) vs. Q4 2021
New holders
8
13 more added
Sold out
9
17 more reduced

Compare with Q4 2021: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting INZY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2022: 50 institutions
Q1 2021: 55 institutionsQ2 2021: 50 institutionsQ3 2021: 52 institutionsQ4 2021: 51 institutionsQ1 2022: 50 institutionsQ2 2022: 47 institutionsQ3 2022: 39 institutionsQ4 2022: 37 institutionsQ1 2023: 50 institutionsQ2 2023: 74 institutionsQ3 2023: 77 institutionsQ4 2023: 80 institutionsQ1 2024: 89 institutionsQ2 2024: 90 institutionsQ3 2024: 89 institutionsQ4 2024: 105 institutionsQ1 2025: 97 institutionsQ2 2025: 87 institutionsQ3 2025: 0 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ1 2022: $71.2M
Q1 2021: $379.4MQ2 2021: $337.1MQ3 2021: $202.7MQ4 2021: $118.2MQ1 2022: $71.2MQ2 2022: $149.4MQ3 2022: $82.7MQ4 2022: $30.4MQ1 2023: $183.4MQ2 2023: $190.3MQ3 2023: $204.6MQ4 2023: $213.3MQ1 2024: $382.0MQ2 2024: $240.1MQ3 2024: $285.5MQ4 2024: $145.1MQ1 2025: $42.5MQ2 2025: $202.3MQ3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding INZY and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 20250$0
Q2 202587$202.3M
Q1 202597$42.5M
Q4 2024105$145.1M
Q3 202489$285.5M
Q2 202490$240.1M
Q1 202489$382.0M
Q4 202380$213.3M
Q3 202377$204.6M
Q2 202374$190.3M
Q1 202350$183.4M
Q4 202237$30.4M
Q3 202239$82.7M
Q2 202247$149.4M
Q1 202250$71.2M
Q4 202151$118.2M
Q3 202152$202.7M
Q2 202150$337.1M
Q1 202155$379.4M

Institutions, Q1 2022

Shares, value and share of portfolio for each institution holding Inozyme Pharma, Inc.; share changes are against Q4 2021.

Institutions holding INZY in Q1 2022
InstitutionSharesValue% of portfolioChange in sharesAction
Toronto Dominion Bank2$00.00%00.0%Unchanged
Ellevest, Inc.38$00.00%+38New
Federated Hermes, Inc.451$2.00K0.00%+330+272.7%Added
Ameritas Investment Partners, Inc.692$3.00K0.00%00.0%Unchanged
Royal Bank of Canada884$4.00K0.00%−2,127−70.6%Reduced
Legal & General Group Plc1,147$5.00K0.00%00.0%Unchanged
Amalgamated Bank1,732$7.00K0.00%+1,732New
Amalgamated Financial Corp.1,732$7.00K0.00%+1,732New
Tower Research Capital LLC (TRC)2,430$10.0K0.00%+1,028+73.3%Added
Wells Fargo & Company2,955$12.0K0.00%−5,028−63.0%Reduced
New York State Common Retirement Fund3,834$16.0K0.00%00.0%Unchanged
California State Teachers Retirement System5,996$25.0K0.00%−1,734−22.4%Reduced
UBS Group AG6,313$26.0K0.00%−915−12.7%Reduced
Bank of America Corp6,647$28.0K0.00%−5,206−43.9%Reduced
American International Group, Inc.7,144$29.0K0.00%−503−6.6%Reduced
Deutsche Bank AG7,810$32.0K0.00%−918−10.5%Reduced
Barclays PLC8,740$36.0K0.00%+8,740New
Laurion Capital Management LP10,000$41.0K0.00%−3,390−25.3%Reduced
PDT Partners, LLC10,273$42.0K0.00%+10,273New
Two Sigma Investments, LP10,916$45.0K0.00%+10,916New
Corton Capital Inc.11,350$46.0K0.02%+11,350New
Renaissance Technologies LLC11,900$49.0K0.00%+11,900New
Citigroup Inc12,517$51.0K0.00%+8,853+241.6%Added
Rhumbline Advisers12,890$53.0K0.00%−174−1.3%Reduced
Goldman Sachs Group Inc13,255$54.0K0.00%+16+0.1%Added
Morgan Stanley15,937$64.0K0.00%−3,503−18.0%Reduced
Overbrook Management Corp16,726$68.0K0.02%00.0%Unchanged
Charles Schwab Investment Management Inc30,497$125.0K0.00%−5,930−16.3%Reduced
Bank of New York Mellon Corp40,013$164.0K0.00%−1,183−2.9%Reduced
Nuveen Asset Management, LLC43,574$172.0K0.00%+1,313+3.1%Added
Bridgeway Capital Management, LLC57,400$235.0K0.00%−20,000−25.8%Reduced
Citadel Advisors LLC98,297$402.0K0.00%−8,681−8.1%Reduced
Baker Bros. Advisors LP106,999$438.0K0.00%00.0%Unchanged
Northern Trust Corp113,823$466.0K0.00%−6,939−5.7%Reduced
Geode Capital Management, LLC186,007$760.0K0.00%+1,988+1.1%Added
State Street Corp189,005$773.0K0.00%+1,903+1.0%Added
MPM Oncology Impact Management LP294,980$1.21M0.32%−7,635−2.5%Reduced
JPMorgan Chase & Co310,933$1.27M0.00%−13,454−4.1%Reduced
Vanguard Group Inc489,613$2.00M0.00%+894+0.2%Added
Janus Henderson Group PLC520,763$2.12M0.00%+395,610+316.1%Added
FMR LLC609,594$2.49M0.00%+2140.0%Added
BlackRock Inc.878,400$3.59M0.00%+41,402+4.9%Added
CHI Advisors LLC892,057$3.65M1.55%00.0%Unchanged
Suvretta Capital Management, LLC1,013,216$4.14M0.13%00.0%Unchanged
Rock Springs Capital Management LP1,193,195$4.88M0.12%+324,729+37.4%Added
Pivotal bioVenture Partners Investment Advisor LLC1,591,154$6.51M3.08%00.0%Unchanged
Adage Capital Partners GP, L.L.C.1,746,672$7.14M0.01%+147,644+9.2%Added
Sofinnova Investments, Inc.2,028,308$8.30M0.70%00.0%Unchanged
Deerfield Management Company, L.P. (Series C)2,344,786$9.59M0.21%00.0%Unchanged
NEA Management Company, LLC2,444,379$10.0M0.32%00.0%Unchanged
OrbiMed Advisors LLC0$00.00%−526,600−100.0%Sold out
Caas Capital Management LP0$00.00%−113,091−100.0%Sold out
Jacobs Levy Equity Management, Inc0$00.00%−88,921−100.0%Sold out
Marshall Wace, LLP0$00.00%−36,033−100.0%Sold out
Millennium Management LLC0$00.00%−19,952−100.0%Sold out
Walleye Capital LLC0$00.00%−15,588−100.0%Sold out
Ergoteles LLC0$00.00%−12,200−100.0%Sold out
Acadian Asset Management LLC0$00.00%−3,676−100.0%Sold out
Amplius Wealth Advisors, LLC0$00.00%−1,000−100.0%Sold out